Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: postprandial distress syndrome.
Functional dyspepsia (FD) is a highly prevalent condition with major socioeconomic and healthcare impact. To date, no pharmacological treatment for FD has been approved. The Rome consensus proposed to subdivide FD into postprandial distress syndrome (PDS), characterized by meal-related symptoms and epigastric pain syndrome, characterized by pain and burning. Acotiamide (Z-338 or YM443) is a new drug, developed for the treatment of FD. Acotiamide enhances acetylcholine release from enteric neurons through muscarinic receptor antagonism and acetycholinesterase inhibition, thereby enhancing gastric emptying and gastric accommodation. Acotiamide was evaluated in FD in clinical studies in Europe, Japan and the USA, beneficial effects were observed for the PDS symptoms of postprandial fullness and early satiation, with a dose of 100 mg three-times a day. A 4-week placebo-controlled Phase III study in PDS patients in Japan confirmed efficacy of acotiamide in relieving postprandial fullness, early satiation and upper abdominal bloating.
Translational Research Center for Gastrointestinal Disorders, University of Leuven, Herestraat 49, 3000 Leuven, Belgium.
Ege
E
Altan
Tatsuhiro
T
Masaoka
Ricard
R
Farré
Jan
J
Tack
D000818:Animals; D001549:Benzamides / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004415:Dyspepsia / Q000188:drug therapy*; D006801:Humans; D019518:Postprandial Period; D013844:Thiazoles / Q000627:therapeutic use*; D016896:Treatment Outcome
D001549:Benzamides; D013844:Thiazoles; C410959:Z 338